Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Dold

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Cell|July 9, 2021
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumChang Liu, Helen M Ginn, Wanwisa Dejnirattisai, et al.
Nature Immunology|December 2, 2021
An immunodominant NP<sub>105-113</sub>-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 diseaseYanchun Peng, Suet Ling Felce, Danning Dong, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Nature Immunology|September 5, 2020
Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19Yanchun Peng, Alexander J Mentzer, Guihai Liu, et al.
Med (New York, N.Y.)|March 2, 2023
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimensShona C Moore, Barbara Kronsteiner, Stephanie Longet, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Wellcome Open Research|March 22, 2021
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory PanelEmily R Adams, Mark Ainsworth, Rekha Anand, et al.
Cell|January 26, 2022
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Cell|July 9, 2021
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumChang Liu, Helen M Ginn, Wanwisa Dejnirattisai, et al.
Nature Immunology|December 2, 2021
An immunodominant NP<sub>105-113</sub>-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 diseaseYanchun Peng, Suet Ling Felce, Danning Dong, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Nature Immunology|September 5, 2020
Broad and strong memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19Yanchun Peng, Alexander J Mentzer, Guihai Liu, et al.
Med (New York, N.Y.)|March 2, 2023
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimensShona C Moore, Barbara Kronsteiner, Stephanie Longet, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Wellcome Open Research|March 22, 2021
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory PanelEmily R Adams, Mark Ainsworth, Rekha Anand, et al.
Cell|January 26, 2022
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Pageof 7